Page:United States Statutes at Large Volume 123.djvu/2137

 123STA T . 211 7PUBLIC LA W 111 –80—O CT. 21 , 200 9authorizedby21U.S. C . 379 h s ha l lbe c redited to this accou n t and re m ain a v ailable until e xp ended , and shall not include any f ees pursuant to 21 U.S.C. 379h ( a ) (2) and (a)(3) assessed for fiscal year 2 0 11 but collected in fiscal year 2010 7,01 4 ,000 shall be derived from medical device user fees authorized by 21 U.S.C. 379 j , and shall be credited to this account and remain available until expended; $17,2 8 0,000 shall be derived from animal dru g user fees authorized by 21 U.S.C. 379j, and shall be credited to this account and remain available until expended; $5,10 6 ,000 shall be derived from animal generic drug user fees authorized by 21 U.S.C. 379f, and shall be credited to this account and shall remain available until expended; and $235,000,000 shall be derived from tobacco product user fees authorized by 21 U.S.C. 387s and shall be credited to this account and remain available until expended
 * $5
 * Provide

d fu r th er, T hat fees derived from prescription drug, medical device, animal drug, animal generic drug, and tobacco product assessments for fiscal year 2010 received during fiscal year 2010, including any such fees assessed prior to fiscal year 2010 but credited for fiscal year 2010, shall be subject to the fiscal year 2010 limitations: Provided further, That in addition and not w ith - standing any other provision under this heading, amounts collected for prescription drug user fees that exceed the fiscal year 2010 limitation are appropriated and shall be credited to this account and remain available until expended: Provided further, That none of these funds shall be used to develop, establish, or operate any program of user fees authorized by 31 U.S.C. 9701: Provided further, That of the total amount appropriated: (1) $782,915,000 shall be for the Center for F ood Safety and A pplied N utrition and related field activities in the O ffice of R egulatory Affairs; (2) $880,104,000 shall be for the Center for D rug E valuation and Research and related field activities in the Office of Regulatory Affairs, of which no less than $51,545,000 shall be available for the Office of G eneric Drugs; (3) $305,249,000 shall be for the Center for B iologics Evalua- tion and Research and for related field activities in the Office of Regulatory Affairs; (4) $155,540,000 shall be for the Center for V eterinary M edicine and for related field activities in the Office of Regulatory Affairs; (5) $349,262,000 shall be for the Center for Devices and Radiological H ealth and for related field activities in the Office of Regulatory Affairs; (6) $58,745,000 shall be for the National Center for Toxicological Research; (7) $216,523,000 shall be for the Center for Tobacco P roducts and for related field activities in the Office of Regulatory Affairs; (8) not to exceed $117,225,000 shall be for Rent and Related activities, of which $41,496,000 is for W hite Oa k Consolidation, other than the amounts paid to the General Services Administration for rent; (9) not to exceed $171,526,000 shall be for payments to the General Services Administration for rent; and (10) $200,129,000 shall be for other activities, including the Office of the Commissioner; the Office of Foods; the Office of the Chief Scientist; the Office of Policy, Planning and Budget; the Office of I nternational Programs; the Office of Administration; and central services for these offices: Provided fur - ther , That none of the funds made available under this heading shall be used to transfer funds under section 770(n) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379dd): Provided further, That not to exceed $25,000 of this amount shall be for official reception and representation expenses, not otherwise provided for, as determined by the Commissioner: Provided further, That funds Fe e s.